NeuroBo Pharmaceuticals, Inc
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NRBO and buy or sell other stocks, ETFs, and their options commission-free!About NRBO
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases.
CEOHyung-Heon Kim
CEOHyung-Heon Kim
Employees9
Employees9
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2014
Founded2014
Employees9
Employees9
NRBO Key Statistics
Market cap324.97M
Market cap324.97M
Price-Earnings ratio-0.52
Price-Earnings ratio-0.52
Dividend yield—
Dividend yield—
Average volume6.86M
Average volume6.86M
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$2.75
52 Week high$2.75
52 Week low$0.5555
52 Week low$0.5555
Stock Snapshot
As of today, NeuroBo Pharmaceuticals, Inc(NRBO) shares are valued at $13.42. The company's market cap stands at 324.97M, with a P/E ratio of -0.52.
During the trading day, NeuroBo Pharmaceuticals, Inc(NRBO) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for NeuroBo Pharmaceuticals, Inc(NRBO) stock has reached 0, versus its average volume of 6.86M.
Over the past 52 weeks, NeuroBo Pharmaceuticals, Inc(NRBO) stock has traded between a high of $2.75 and a low of $0.56.
Over the past 52 weeks, NeuroBo Pharmaceuticals, Inc(NRBO) stock has traded between a high of $2.75 and a low of $0.56.
People also own
Based on the portfolios of people who own NRBO. This list is generated using Robinhood data, and it’s not a recommendation.